Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine for Impulsivity in Tourette's Syndrome
NCT04354103Phase 2Terminated
- Sponsor
- CHU de Poitiers
- Start
- May 2022
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of atomoxetine in Tourette syndrome (TS), sponsored by CHU de Poitiers. Started May 2022; status: terminated.
02
Drugs
atomoxetine
03
Conditions
Tourette syndrome (TS)
Beyond the preview
Go deeper on NCT04354103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04354103.